DOCSLIB.ORG

Non-Hodgkin Lymphoma Therapy Landscape

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Non-Hodgkin Lymphoma Therapy Landscape NEWS & ANALYSIS FROM THE ANALYST’S COUCH Non-Hodgkin lymphoma therapy landscape Kritika Chaudhari, Salman Rizvi and Basharut A. Syed Quality Stock/Alamy Stock Photo Credit: Non- Hodgkin lymphoma (NHL) comprises and/or δ (PI3Kγ/δ) inhibitors, idelalisib response after two cycles of chemotherapy. a wide spectrum of lymphoid neoplasms (Zydelig; Gilead Sciences), copanlisib Although blinatumomab is associated that affect approximately 1.5 million people (Aliqopa; Bayer HealthCare Pharmaceuticals) with substantial neurological toxicity and worldwide. B cell lymphomas (BCLs) account and duvelisib (Copiktra; Verastem Oncology). a cumbersome administration schedule for the majority (>85%) of cases of NHL; The FDA has also granted approval to — continuous infusion via an ambulatory the others are derived from T cells or natural pembrolizumab (Keytruda; Merck & Co.), pump for 4 to 8 weeks — the drug shows killer cells. NHL is frequently categorized a PD1 inhibitor, for patients with R/R an overall response rate (ORR) of 69% and by prognosis into slow- progressing or primary mediastinal BCL. complete response (CR) in 37% of patients indolent NHL (iNHL), or fast-progressing Options for patients who have exhausted across all subtypes. or aggressive NHL (aNHL). Follicular prior lines of therapy include the CD19 Roche’s polatuzumab vedotin, an lymphoma (FL) and diffuse large BCL chimeric antigen receptor (CAR)-T cell anti- CD79B ADC, is being evaluated in (DLBCL) are the most common indolent therapies tisagenlecleucel (Kymriah; combination with chemotherapy plus and aggressive subtypes, respectively, and Novartis) and axicabtagene ciloleucel rituximab for the treatment of patients account for around one-fifth and one-third (Yescarta; Kite Pharma), which were with previously untreated DLBCL. of NHL cases each. approved in 2017. Treatment with these Although there was no difference in CAR- T cell therapies carries a risk of cytokine survival in the phase II data for patients Current treatments release syndrome and neurological toxicities. with FL, the results for those with DLBCL Clinical guidelines recommend the Moreover, the high costs — from US$373,000 were highly encouraging (PFS of 6.7 months use of anti-CD20 immunotherapy — to $475,000 — and logistical challenges versus 2 months, and a median overall mainly rituximab (Rituxan; Roche) or of delivering CAR-T treatments present a survival of 11.8 months versus 4.7 months for obinutuzumab (Gazyva; Roche, FL only) serious concern. polatuzumab vedotin plus bendamustine and — combined with chemotherapy agents rituximab (BR) compared with BR alone), such as bendamustine or the four-drug Emerging therapies auguring well for the ongoing phase III cyclophosphamide, doxorubicin, vincristine A number of promising NHL therapies POLARIX study, which has an expected and prednisone (CHOP) regimen as the are in development (TABLE 1). Amgen’s primary completion date of December first- line option. Response rates for most blinatumomab (Blincyto), a bispecific 2019. The efficacy and safety profile of subtypes of NHL are high (DLBCL 80%; FL T cell engager (BiTE) antibody construct polatuzumab vedotin is expected to be 90%) with a 3-year progression-free survival that binds to CD3 on T cells and CD19 similar to that of brentuximab vedotin and (PFS) of around 70%, but many patients on B cells and is approved for B cell acute has the potential to change the front-line relapse. Therapy for relapsed/refractory lymphoblastic leukemia, is in phase II/III standard of care for DLBCL. (R/R) NHL remains challenging and trials in patients with R/R aggressive B cell MOR208 (MorphoSys/Xencor), a CD19- tends to be customized and driven by NHL who do not have a complete metabolic targeting monoclonal antibody (mAb), physician and patient preferences, but typically involves anti- CD20 antibodies and chemotherapy. The immunomodulatory Table 1 | Selected products in late-stage development for NHL drug lenalidomide (Revlimid; Celgene) Drug Developer Mode of action Status in combination with rituximab is also available to patients who are not eligible Blinatumomab Amgen CD19 BiTE mAb Phase III for high- dose chemotherapy. For eligible Polatuzumab vedotin Roche CD79B ADC Phase III patients, high- dose chemotherapy supported MOR208 MorphoSys/Xencor CD19 mAb Phase II/III by autologous stem cell transplantation can Enzastaurin Denovo Pharma PKCβ/AKT inhibitor Phase III induce prolonged remission. Recent approvals for treating R/R NHL Duvelisib Verastem PI3Kγ/δ inhibitor Phase II subtypes include the CD30-targeting Umbralisib TG Therapeutics PI3Kδ inhibitor Phase II antibody–drug conjugate (ADC) Venetoclax AbbVie/Roche BCL2 inhibitor Phase II/III brentuximab vedotin (Adcetris; Seattle Nivolumab Bristol- Myers Squibb PD1 inhibitor Phase II/III Genetics), two Bruton's tyrosine kinase (BTK) inhibitors, ibrutinib (Imbruvica; Avelumab Merck KGaA/Pfizer PDL1 inhibitor Phase II Janssen Biotech/Pharmacyclics (AbbVie)) and JCAR017 Juno Therapeutics/Celgene CAR- T therapy Phase II acalabrutinib (Calquence; AstraZeneca), ADC, antibody–drug conjugate; BCL2, B cell lymphoma 2; BiTE, bispecific T cell engager ; CAR , chimeric and three phosphoinositide 3-kinase γ antigen receptor ; PKCβ, protein kinase C β; PI3K , phosphoinositide 3-kinase. NatURE REVIEWS | DRUG DISCOVERY VOLUME 18 | SEPTEMBER 2019 | 663 NEWS & ANALYSIS 2018 2023 T cell lymphoma. Although PI3K inhibitors have been associated with high levels of 0.1 0.6 1.6 toxicity, umbralisib, owing to its improved 0.4 0.2 safety profile, could challenge both idelalisib 0.4 and copanlisib as a later-line option for US$6.4 US$9.3 1.2 Anti-CD20 mAbs BCLs. However, for market penetration, billion billion Kinase inhibitors 4.7 a head- to-head comparison with rituximab, Chemotherapy agents 2.4 the current gold standard, will be required. 4.1 IMiDs/PIs Others Market indicators The worldwide NHL market generated Fig. 1 | Non- Hodgkin lymphoma worldwide drug sales ($US billions, 2018 and 2023). revenues of $6.4 billion in 2018, a substantial IMiDs, immunomodulatory drugs; mAbs, monoclonal antibodies; PIs, protease inhibitors. increase from the 2013 value of $4.5 billion (2013–2018 compound annual growth rate (CAGR) of 7.3%) (FIG. 1). In 2018, anti-CD20 is being evaluated in a phase II/III study could find a role in NHL if used in the right mAbs, namely rituximab and obinutuzumab, (B- MIND) in combination with combination. dominated the NHL market, accounting bendamustine versus BR in R/R DLBCL. Juno Therapeutics/Celgene’s lead for 65% of the sales, followed by targeted In the phase II L-MIND study, MOR208 anti- CD19 CAR- T candidate, lisocabtagene small- molecule BTK or PI3Kγ/δ inhibitors was well tolerated and had an ORR of 49% maraleucel (JCAR017), is in a phase II (ibrutinib and idelalisib) with collective sales with 29 of 33 responses ongoing and a CR (PLATFORM) exploratory study in of $1.2 billion (19% of sales). Lenalidomide in 31% of patients with R/R DLBCL when R/R B cell malignancies. Published data and bortezomib (Velcade; Takeda/Johnson used in combination with lenalidomide. suggest that JCAR017 has potentially lower & Johnson) contributed ~2% of total NHL However, mAbs targeting CD40, CD22 or toxicity than existing CAR- T therapies sales in 2018. human leukocyte antigen-DR in lymphomas and might be delivered in an outpatient The NHL market is projected to reach failed to outperform rituximab and setting. Such deployment will both improve $9.3 billion by 2023 (CAGR of 7.7% in whether a CD19-targeted mAb does so in a patient satisfaction and drastically reduce 2018–2023), driven largely by premium- pivotal phase III study remains to be seen; treatment costs. priced biologic and targeted therapies. if successful, MOR208 in combination with Several small molecules that target Polatuzumab vedotin, MOR208 and chemotherapy could provide an alternative survival pathways are also in late-stage venetoclax are expected to reach the market front- line option for DLBCL. Moreover, development. Of note, venetoclax during the forecast period. In addition, anti- CD19 antibody- based therapies could (Venclexta/Venclyxto; AbbVie/Roche), CAR- T therapies are emerging as arguably potentially be a cheaper alternative to a BCL2 inhibitor, is currently in a the most promising treatment option for anti- CD19 CAR- T therapies. phase II/III (SYMPATICO) trial with most NHL subtypes. Their safety, logistics Novartis’s ofatumumab (Arzerra), ibrutinib for mantle cell lymphoma. and cost effectiveness in the long run will a CD20-targeted mAb already approved Venetoclax is approved for second-line determine uptake. in R/R chronic lymphocytic leukaemia CLL; surprisingly, it failed to show efficacy Importantly, with the loss of exclusivity (CLL), was evaluated in a phase III in patients with FL. The combination of for rituximab, the growth of the anti-CD20 (COMPLEMENT A+B) study in venetoclax and ibrutinib with an anti-CD20 mAb class is likely to be hampered by the combination with bendamustine in B cell mAb could further enhance the efficacy entry of biosimilars, including Truxima iNHL that is unresponsive to rituximab. of the treatment regimen. (Celltrion) and Rixathon/Riximyo (Sandoz), Top- line results failed to show any significant Of the three oral kinase inhibitors in both of which have been approved. improvement in PFS. Previously, in the development, Denovo Pharma’s enzastaurin A subcutaneous version of rituximab (Hycela) ORCHARD study, in the R/R DLBCL is the most advanced, as it is in a phase III and obinutuzumab, a second- generation setting, ofatumumab was not associated with (ENGINE) study in combination with anti- CD20 product, may slow the expected improved outcomes relative to rituximab rituximab plus CHOP as a first-line erosion during the forecast period. Despite treatment. Ofatumumab and rituximab treatment for patients with de novo genomic the progress, significant unmet needs target different epitopes on CD20. marker 1 (DGM1)-positive high-risk remain in NHL treatment; in addition Two checkpoint inhibitors are also DLBCL. Enzastaurin is thought to target to effective and curative modalities, progressing through the NHL pipeline. protein kinase C β (PKCβ) and/or AKT.
Load more

Recommended publications
  • Proteomics and Drug Repurposing in CLL Towards Precision Medicine
    cancers Review Proteomics and Drug Repurposing in CLL towards Precision Medicine Dimitra Mavridou 1,2,3, Konstantina Psatha 1,2,3,4,* and Michalis Aivaliotis 1,2,3,4,* 1 Laboratory of Biochemistry, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, GR-54124 Thessaloniki, Greece; [email protected] 2 Functional Proteomics and Systems Biology (FunPATh)—Center for Interdisciplinary Research and Innovation (CIRI-AUTH), GR-57001 Thessaloniki, Greece 3 Basic and Translational Research Unit, Special Unit for Biomedical Research and Education, School of Medicine, Aristotle University of Thessaloniki, GR-54124 Thessaloniki, Greece 4 Institute of Molecular Biology and Biotechnology, Foundation of Research and Technology, GR-70013 Heraklion, Greece * Correspondence: [email protected] (K.P.); [email protected] (M.A.) Simple Summary: Despite continued efforts, the current status of knowledge in CLL molecular pathobiology, diagnosis, prognosis and treatment remains elusive and imprecise. Proteomics ap- proaches combined with advanced bioinformatics and drug repurposing promise to shed light on the complex proteome heterogeneity of CLL patients and mitigate, improve, or even eliminate the knowledge stagnation. In relation to this concept, this review presents a brief overview of all the available proteomics and drug repurposing studies in CLL and suggests the way such studies can be exploited to find effective therapeutic options combined with drug repurposing strategies to adopt and accost a more “precision medicine” spectrum. Citation: Mavridou, D.; Psatha, K.; Abstract: CLL is a hematological malignancy considered as the most frequent lymphoproliferative Aivaliotis, M. Proteomics and Drug disease in the western world. It is characterized by high molecular heterogeneity and despite the Repurposing in CLL towards available therapeutic options, there are many patient subgroups showing the insufficient effectiveness Precision Medicine.
    [Show full text]
  • Activity of Rituximab and Ofatumumab Against Mantle
    ACTIVITY OF RITUXIMAB AND OFATUMUMAB AGAINST MANTLE CELL LYMPHOMA(MCL) IN VITRO IN MCL CELL LINES BY COMPLEMENT DEPENDENT CYTOTOXICITY (CDC)AND ANTIBODY-DEPENDENT CELL MEDIATED CYTOTOXICITY ASSAYS(ADCC) Dr. Gopichand Pendurti M.B.B.S Mentor: Dr. Francisco J. Hernandez-Ilizaliturri MD Overview of presentation •Introduction to mantle cell lymphoma. •Concept of minimal residual disease. •Anti CD 20 antibodies. •51Cr release assays. •Flow cytometry on cell lines. •Results. •Future. MANTLE CELL LYMPHOMA •Mantle cell lymphoma is characterized by abnormal proliferation of mature B lymphocytes derived from naïve B cells. •Constitutes about 5% of all patients with Non Hodgkin's lymphoma. •Predominantly in males with M:F ratio 2.7:1 with onset at advanced age (median age 60yrs). •It is an aggressive lymphoma with median survival of patients being 3-4 years. •Often presents as stage III-IV with lymphadenopathy, hepatosplenomegaly, gastrointestinal involvement, peripheral blood involvement. Pedro Jares, Dolors Colomer and Elias Campo Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics Nature revision of cancer 2007 October:7(10):750-62 •Genetic hallmark is t(11:14)(q13:q32) translocation leading to over expression of cyclin D1 which has one of the important pathogenetic role in deregulating the cell cycle. •Other pathogentic mechanisms include molecular and chromosomal alterations that Target proteins that regulate the cell cycle and senecense (BMI1,INK4a,ARF,CDK4 AND RB1). Interfere with cellular
    [Show full text]
  • Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
    Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models.
    [Show full text]
  • 1 Activity of the Second Generation BTK Inhibitor Acalabrutinib In
    Activity of the Second Generation BTK Inhibitor Acalabrutinib in Canine and Human B-cell Non-Hodgkin Lymphoma Dissertation Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Bonnie Kate Harrington Graduate Program in Comparative and Veterinary Medicine The Ohio State University 2018 Dissertation Committee John C. Byrd, M.D., Advisor Amy J. Johnson, Ph.D. Krista La Perle, D.V.M., Ph.D. William C. Kisseberth, D.V.M., Ph.D. 1 Copyrighted by Bonnie Kate Harrington 2018 2 Abstract Acalabrutinib (ACP-196) is a second-generation inhibitor of Bruton’s Tyrosine Kinase (BTK) with increased target selectivity and potency compared to ibrutinib. In these studies, we evaluated acalabrutinib in spontaneously occurring canine lymphoma, a model of B-cell malignancy reported to be similar to human diffuse large B-cell lymphoma (DLBCL), as well as primary human chronic lymphocytic leukemia (CLL) cells. We demonstrated that acalabrutinib potently inhibited BTK activity and downstream B-cell receptor (BCR) effectors in CLBL1, a canine B-cell lymphoma cell line, primary canine lymphoma cells, and primary CLL cells. Compared to ibrutinib, acalabrutinib is a more specific inhibitor and lacked off-target effects on the T-cell and NK cell kinase IL-2 inducible T-cell kinase (ITK) and epidermal growth factor receptor (EGFR). Accordingly, acalabrutinib did not antagonize antibody dependent cell cytotoxicity mediated by NK cells. Finally, acalabrutinib inhibited proliferation and viability in CLBL1 cells and primary CLL cells and abrogated chemotactic migration in primary CLL cells. To support our in vitro findings, we conducted a clinical trial using companion dogs with spontaneously occurring B-cell lymphoma.
    [Show full text]
  • Ublituximab (TG-1101) in Combination with Umbralisib (TGR-1202) for Chronic Lymphocytic Leukaemia NIHRIO (HSRIC) ID: 12230 NICE ID: 9540
    NIHR Innovation Observatory Evidence Briefing: SEPTEMBER 2017 Ublituximab (TG-1101) in combination with umbralisib (TGR-1202) for chronic lymphocytic leukaemia NIHRIO (HSRIC) ID: 12230 NICE ID: 9540 LAY SUMMARY Chronic lymphocytic leukaemia is a type of blood cancer that develops inside the bone marrows. This produces abnormal types of white blood cells (lymphocytes) which do not function properly, hence, do not protect from infections the way they should do. Chronic types of leukaemia develop slowly over a long time. Symptoms of this cancer usually only develop at a later stage of the disease. They may include frequent infections, persistent tiredness, shortness of breath, pale skin, bleeding and bruising more easily and others. The cause of chronic lymphocytic leukaemia is not yet fully understood but risk factors may include age (older people), exposure to chemicals, family history, gender or ethnicity. Ublituximab in combination with umbralisib is under development for the treatment of chronic lymphocytic leukaemia and other types of blood cancers. They both act in different ways to suppress the production and growth of the abnormal lymphocytes caused by bindings to certain cells and proteins in the body that produces the cancer. If licensed, it will offer an additional treatment option for patients with chronic lymphocytic leukaemia. This briefing is based on information available at the time of research and a limited literature search. It is not intended to be a definitive statement on the safety, efficacy or effectiveness of the health technology covered and should not be used for commercial purposes or commissioning without additional information. This briefing presents independent research funded by the National Institute for Health Research (NIHR).
    [Show full text]
  • Inhibitors Targeting Bruton’S Tyrosine Kinase in Cancers
    Leukemia (2021) 35:312–332 https://doi.org/10.1038/s41375-020-01072-6 REVIEW ARTICLE Lymphoma Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances 1 2 1 2 1 Tingyu Wen ● Jinsong Wang ● Yuankai Shi ● Haili Qian ● Peng Liu Received: 2 April 2020 / Revised: 27 September 2020 / Accepted: 15 October 2020 / Published online: 29 October 2020 © The Author(s) 2020. This article is published with open access Abstract Bruton’s tyrosine kinase (BTK) inhibitor is a promising novel agent that has potential efficiency in B-cell malignancies. It took approximately 20 years from target discovery to new drug approval. The first-in-class drug ibrutinib creates possibilities for an era of chemotherapy-free management of B-cell malignancies, and it is so popular that gross sales have rapidly grown to more than 230 billion dollars in just 6 years, with annual sales exceeding 80 billion dollars; it also became one of the five top-selling medicines in the world. Numerous clinical trials of BTK inhibitors in cancers were initiated in the last decade, and ~73 trials were intensively announced or updated with extended follow-up data in the most recent 3 years. In this review, we summarized the significant milestones in the preclinical discovery and clinical development of BTK inhibitors to better 1234567890();,: 1234567890();,: understand the clinical and commercial potential as well as the directions being taken. Furthermore, it also contributes impactful lessons regarding the discovery and development of other novel therapies. Introduction (DLBCL), follicular lymphoma (FL), multiple myeloma (MM), marginal zone lymphoma (MZL), mantle cell lym- B-cell malignancies include non-Hodgkin lymphomas phoma (MCL) and Waldenström’s macroglobulinemia (NHLs) and chronic lymphocytic leukaemia.
    [Show full text]
  • Antibody–Drug Conjugates
    Published OnlineFirst April 12, 2019; DOI: 10.1158/1078-0432.CCR-19-0272 Review Clinical Cancer Research Antibody–Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index Steven Coats1, Marna Williams1, Benjamin Kebble1, Rakesh Dixit1, Leo Tseng1, Nai-Shun Yao1, David A. Tice1, and Jean-Charles Soria1,2 Abstract Since the first approval of gemtuzumab ozogamicin nism of activity of the cytotoxic warhead. However, the (Mylotarg; Pfizer; CD33 targeted), two additional antibody– enthusiasm to develop ADCs has not been dampened; drug conjugates (ADC), brentuximab vedotin (Adcetris; Seat- approximately 80 ADCs are in clinical development in tle Genetics, Inc.; CD30 targeted) and inotuzumab ozogami- nearly 600 clinical trials, and 2 to 3 novel ADCs are likely cin (Besponsa; Pfizer; CD22 targeted), have been approved for to be approved within the next few years. While the hematologic cancers and 1 ADC, trastuzumab emtansine promise of a more targeted chemotherapy with less tox- (Kadcyla; Genentech; HER2 targeted), has been approved to icity has not yet been realized with ADCs, improvements treat breast cancer. Despite a clear clinical benefit being dem- in technology combined with a wealth of clinical data are onstrated for all 4 approved ADCs, the toxicity profiles are helping to shape the future development of ADCs. In this comparable with those of standard-of-care chemotherapeu- review, we discuss the clinical and translational strategies tics, with dose-limiting toxicities associated with the mecha- associated with improving the therapeutic index for ADCs. Introduction in antibody, linker, and warhead technologies in significant depth (2, 3, 8, 9). Antibody–drug conjugates (ADC) were initially designed to leverage the exquisite specificity of antibodies to deliver targeted potent chemotherapeutic agents with the intention of improving Overview of ADCs in Clinical Development the therapeutic index (the ratio between the toxic dose and the Four ADCs have been approved over the last 20 years (Fig.
    [Show full text]
  • Refreshing the Biologic Pipeline 2020
    news feature Credit: Science Lab / Alamy Stock Photo Refreshing the biologic pipeline 2020 In the absence of face-to-face meetings, FDA and industry implemented regulatory workarounds to maintain drug and biologics approvals. These could be here to stay. John Hodgson OVID-19 might have been expected since 1996) — a small miracle in itself “COVID-19 confronted us with the need to severely impair drug approvals (Fig. 1 and Table 1). to better triage sponsors’ questions,” says Cin 2020. In the event, however, To the usual crop of rare disease and Peter Marks, the director of the Center for industry and regulators delivered a small genetic-niche cancer treatments, 2020 Biologics Evaluation and Research (CBER) miracle. They found workarounds and also added a chimeric antigen receptor at the FDA. “That was perhaps the single surrogate methods of engagement. Starting (CAR)-T cell therapy with a cleaner biggest takeaway from the pandemic related in January 2020, when the outbreak veered manufacturing process and the first to product applications.” Marks says that it westward, the number of face-to face approved blockbuster indication for a became very apparent with some COVID- meetings declined rapidly; by March, small-interfering RNA (siRNA) — the 19-related files that resolving a single they were replaced by Webex and Teams. European Medicines Agency’s (EMA) issue can help a sponsor enormously and (Secure Zoom meeting are to be added registration of the RNA interference accelerate the development cycle. Before this year.) And remarkably, by 31 December, (RNAi) therapy Leqvio (inclisiran) for COVID-19, it was conceivable that a small the US Food and Drug Administration cardiovascular disease.
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • The Future of Antibodies As Cancer Drugs
    REVIEWS Drug Discovery Today Volume 17, Numbers 17/18 September 2012 The biopharmaceutical industry’s pipeline of anticancer antibodies includes 165 candidates with substantial diversity in composition, targets and mechanisms of action that hold promise to be the cancer drugs of the future. Reviews FOUNDATION REVIEW Foundation review: The future of antibodies as cancer drugs 1 2 Dr Janice Reichert Janice M. Reichert and Eugen Dhimolea is Research Assistant Professor at Tufts 1 Center for the Study of Drug Development, Tufts University School of Medicine, 75 Kneeland Street, University’s Center for the Study of Drug Development Suite 1100, Boston, MA 02111, USA 2 (CSDD). She is also Founder Department of Medical Oncology, Dana-Farber Cancer Institute/Harvard Medical School, 77 Louis Pasteur Ave., and Editor-in-Chief of mAbs, Harvard Institutes of Medicine, Room 309, Boston, MA 02215, USA a peer-reviewed, PubMed- indexed biomedical journal that focuses on topics relevant to antibody research Targeted therapeutics such as monoclonal antibodies (mAbs) have proven and development; President of the board of directors of The Antibody Society; and a member of the board successful as cancer drugs. To profile products that could be marketed in of the Peptide Therapeutics Foundation. At CSDD, the future, we examined the current commercial clinical pipeline of mAb Dr Reichert studies innovation in the pharmaceutical and biotechnology industries. Her work focuses on candidates for cancer. Our analysis revealed trends toward development of strategic analyses of investigational candidates and marketed products, with an emphasis on the clinical a variety of noncanonical mAbs, including antibody–drug conjugates development and approval of new therapeutics and (ADCs), bispecific antibodies, engineered antibodies and antibody vaccines.
    [Show full text]
  • Whither Radioimmunotherapy: to Be Or Not to Be? Damian J
    Published OnlineFirst April 20, 2017; DOI: 10.1158/0008-5472.CAN-16-2523 Cancer Perspective Research Whither Radioimmunotherapy: To Be or Not To Be? Damian J. Green1,2 and Oliver W. Press1,2,3 Abstract Therapy of cancer with radiolabeled monoclonal antibodies employing multistep "pretargeting" methods, particularly those has produced impressive results in preclinical experiments and in utilizing bispecific antibodies, have greatly enhanced the thera- clinical trials conducted in radiosensitive malignancies, particu- peutic efficacy of radioimmunotherapy and diminished its toxi- larly B-cell lymphomas. Two "first-generation," directly radiola- cities. The dramatically improved therapeutic index of bispecific beled anti-CD20 antibodies, 131iodine-tositumomab and 90yttri- antibody pretargeting appears to be sufficiently compelling to um-ibritumomab tiuxetan, were FDA-approved more than a justify human clinical trials and reinvigorate enthusiasm for decade ago but have been little utilized because of a variety of radioimmunotherapy in the treatment of malignancies, particu- medical, financial, and logistic obstacles. Newer technologies larly lymphomas. Cancer Res; 77(9); 1–6. Ó2017 AACR. "To be, or not to be, that is the question: Whether 'tis nobler in the pembrolizumab (anti-PD-1), which are not directly cytotoxic mind to suffer the slings and arrows of outrageous fortune, or to take for cancer cells but "release the brakes" on the immune system, arms against a sea of troubles, And by opposing end them." Hamlet. allowing cytotoxic T cells to be more effective at recognizing –William Shakespeare. and killing cancer cells. Outstanding results have already been demonstrated with checkpoint inhibiting antibodies even in far Introduction advanced refractory solid tumors including melanoma, lung cancer, Hodgkin lymphoma and are under study for a multi- Impact of monoclonal antibodies on the field of clinical tude of other malignancies (4–6).
    [Show full text]
  • Comparison of Acalabrutinib, a Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells
    Author Manuscript Published OnlineFirst on December 29, 2016; DOI: 10.1158/1078-0432.CCR-16-1446 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Comparison of acalabrutinib, a selective Bruton tyrosine kinase inhibitor, with ibrutinib in chronic lymphocytic leukemia cells Viralkumar Patel,1 Kumudha Balakrishnan,1 Elena Bibikova3, Mary Ayres,1 Michael J. Keating,2 William G. Wierda,2 and Varsha Gandhi1,2 1Department of Experimental Therapeutics and 2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX; and 3Acerta Pharma, Redwood City, CA. Correspondence: Varsha Gandhi, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Unit 1950, 1901 East Road, Houston, TX 77054; Tel.: 713- 792-2989; Fax: 713-745-1710; e-mail: [email protected]. Conflict of Interest Disclosure: V.G. and W.G.W. received research and clinical trial funding from Acerta Pharma. E.B. is an employee of Acerta Pharma. The other authors do not have conflicts of interest. Running title: Acalabrutinib compared with ibrutinib in CLL cells Keywords: ibrutinib, acalabrutinib, chronic lymphocytic leukemia, apoptosis, Bruton tyrosine kinase Financial Support: This work was supported in part by grant CLL P01 CA81534 from the National Cancer Institute, by a Sponsored Research Agreement from Acerta Pharma, and by The University of Texas MD Anderson Cancer Center Moon Shot Program. MD Anderson Cancer Center is supported in part by the National Institutes of Health through Cancer Center Support Grant P30CA016672. Word count: Translational Relevance (113 words), Abstract (234 words), Text (3570 words) Figure and Table count: 6 figures; Reference count: 51; Supplementary data: 2 tables, 1 figure Scientific category: Cancer Therapy: Preclinical 1 Downloaded from clincancerres.aacrjournals.org on September 30, 2021.
    [Show full text]